The presence of a possible correlation between changes in left ventricular mass of hypertensive patients and the degree of blood pressure reduction with different antihypertensive drugs has been investigated in 40 outpatients by M-mode echocardiography. Ten of these, with blood pressure in normal limits with different antihypertensive treatment had their therapy changed in chlorthalidone 25 mg/day without any run-in (Group A); other 30 patients, with a previously uncontrolled blood pressure, after a 14 day run-in, were randomly allocated to chlorthalidone 25 mg/day (Group B), slow release nifedipine 20 mg/day (Group C) or placebo (Group D). At the end of the eight week treatment period a further decrease in systolic blood pressure was observed in Group A without changes in ventricular mass; an highly significant decrease in both systolic and diastolic blood pressure was observed in B and C but only patients on chlorthalidone changed their ventricular mass; no change in both blood pressure and ventricular mass was observed on placebo. As changes in ventricular mass are not correlated with blood pressure reduction, we conclude that other, not well defined factors, apart from the decrease in duration and degree of left ventricular systolic wall tension, may be responsable for reversal of left ventricular hypertrophy.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Sokolow M, Perloff D (1961) The prognosis of essential hypertension treated conservatively. Circulation 23: 697–713
Alcocer L, Aspe J (1979) The effect of antihypertensive treatment with methyldopa on left ventricular mass. In: Robertson JIS, Caldwell ADS (eds) Left ventricular hypertrophy in hypertension. Grune & Stratton, New York, p 94
Reichek M, Franklin BB, Chandler T, Muhamad A, Plappert T, St John Sutton M (1982) Reversal of left ventricular hypertrophy by antihypertensive therapy. Eur Heart J [Suppl A]: 165–169
Fouad FM, Nakashima Y, Tarazi RC, Salcedo EE (1982) Reversal of left ventricular hypertrophy with methyldopa. Am J Cardiol 49: 795–801
Ibrahim MM, Madkour MA, Mossallam R (1980) Effect of atenolol on left ventricular function on hypertensive patients. Circulation 62: 1036–1046
Hill LS, Monaghan M, Richardson PJ (1979) Regression of left ventricular hypertrophy during treatment with antihypertensive agents. Br J Clin Pharmacol 7 [Suppl 2]: 255–259
Drayer JIM, Gardin JM, Weber MA, Aronow WS (1982) Changes in left ventricular septal thickness during diuretic therapy. Clin Pharmacol Ther 32: 283–288
Ferrara LA, de Simone G, Pasanisi F, Mancini Marcello, Mancini M (1984) Left ventricular mass reduction during salt depletion in arterial hypertension. Hypertension 6 (in press)
Ostman I, Sjostrand NO, Swedin G (1972) Cardiac noradrenaline turnover and urinary catecholamines excretion in trained and untrained rats during rest and exercise. Acta Physiol Scand 86: 299–308
Gans JH, Cater MR (1970) Norepinephrine induced cardiac hypertrophy in dogs. Life Sci 9: 731–734
Laks MM, Morady F, Swant HJC (1973) Myocardial hypertrophy produced by chronic infusion of subhypertensive doses of norepinephrine in the dog. Chest 64: 75–78
Ostman-Smith I (1981) Cardiac Sympathetic nerves as the final pathway in the induction of cardiac hypertrophy. Clin Sci 61: 265–272
Womble JR, Haddox MK, Russel DH (1978) Epinephrine elevation in plasma parallels canine cardiac hypertrophy. Life Sci 23: 1951–1958
Ostman-Smith I (1976) Prevention of exercise-induced cardiac hypertrophy in rats by chemical sympathectomy (guanethidine treatment). Neuroscience 1: 497–507
Yamori Y, Tarazi RC, Ooshima A (1980) Effect of beta-receptor blocking agents on cardiovascular structural changes in spontaneous and noradrenaline induced hypertension in rats. Clin Sci 59: 457s
Tarazi RC, Sen S, Saragoga M, Khairallah P (1982) The multifactorial role of catecholamines in hypertensive cardiac hypertrophy. Eur Heart J 3 [Suppl A]: 103–110
Caldarera CM, Casti A, Rossoni C, Visioli O (1971) Polyamines and noradrenaline following myocardial hypertrophy. J Mol Cell Cardiol 3: 121–126
Caldarera CM, Orlandini G, Casti A, Moruzzi G (1974) Polyamines and nucleic acid metabolism in myocardial hypertrophy of the overloaded heart. J Mol Cell Cardiol 6: 95–104
Weissler AM, Harris WB, Schoenfeld CD (1968) Systolic time intervals in heart failure in man. Circulation 37: 149–159
Lewis RP, Rittgers SE, Forester WF, Boudoulas H (1977) A critical review of systolic time intervals. Circulation 56: 146–158
About this article
Cite this article
Ferrara, L.A., de Simone, G., Mancini, M. et al. Changes in left ventricular mass during a double-blind study with chlorthalidone and slow-release nifedipine. Eur J Clin Pharmacol 27, 525–528 (1984). https://doi.org/10.1007/BF00556886
- left ventricular mass
- slow-release nifedipine